Merck to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October 25
23 September 2016 - 10:00PM
Business Wire
Merck (NYSE:MRK), known as MSD outside the United States and
Canada, will hold its third-quarter 2016 sales and earnings
conference call with institutional investors and analysts at 8:00
a.m. EDT on Tuesday, Oct. 25. During the call, company executives
will provide an overview of Merck’s performance for the
quarter.
Investors, journalists and the general public may access a live
audio webcast of the call on Merck’s website at
http://investors.merck.com/investors/webcasts-and-presentations/default.aspx.
A replay of the webcast, along with the sales and earnings news
release and supplemental financial disclosures, will be available
at www.merck.com.
Institutional investors and analysts can participate in the call
by dialing (706) 758-9927 or (877) 381-5782 and using ID code
number 87561377. Members of the media are invited to monitor the
call by dialing (706) 758-9928 or (800) 399-7917 and using ID code
number 87561377. Journalists who wish to ask questions are
requested to contact a member of Merck’s Media Relations team at
the conclusion of the call.
About Merck
For 125 years, Merck has been a global health care leader
working to help the world be well. Merck is known as MSD outside
the United States and Canada. Through our prescription medicines,
vaccines, biologic therapies and animal health products, we work
with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies,
programs and partnerships. For more information, visit
www.merck.com and connect with us on Twitter, Facebook, YouTube and
LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2015
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160923005178/en/
MerckMedia:Lainie Keller, 908-236-5036orInvestors:Teri Loxam,
908-740-1986Amy Klug, 908-740-1898
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024